{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T08:10:09Z","timestamp":1715155809728},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00705-013-1687-6","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T06:28:18Z","timestamp":1364970498000},"page":"1907-1915","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin"],"prefix":"10.1007","volume":"158","author":[{"given":"M.","family":"Sede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Quarleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"1687_CR1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","volume":"5","author":"D Moradpour","year":"2007","unstructured":"Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453\u2013463","journal-title":"Nat Rev Microbiol"},{"key":"1687_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","volume":"18","author":"J Medrano","year":"2011","unstructured":"Medrano J, Resino S, Vispo E, Madejon A, Labarga P et al (2011) Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV\/HCV-coinfected patients. J Viral Hepat 18:325\u2013330","journal-title":"J Viral Hepat"},{"key":"1687_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QAI.0b013e31824f5506","volume":"60","author":"NI Rallon","year":"2012","unstructured":"Rallon NI, Pineda JA, Soriano V, Neukam K, Vispo E et al (2012) Differences in virological response to peginterferon-alpha plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J Acquir Immune Defic Syndr 60:117\u2013123","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1687_CR4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.21990","volume":"47","author":"JC Duclos-Vallee","year":"2008","unstructured":"Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM et al (2008) Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47:407\u2013417","journal-title":"Hepatology"},{"key":"1687_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CCO.0b013e328355e0d7","volume":"24","author":"NN Nissen","year":"2012","unstructured":"Nissen NN, Barin B, Stock PG (2012) Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 24:517\u2013521","journal-title":"Curr Opin Oncol"},{"key":"1687_CR6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/apc.2007.0199","volume":"22","author":"G Liu-Young","year":"2008","unstructured":"Liu-Young G, Kozal MJ (2008) Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 22:449\u2013457","journal-title":"AIDS Patient Care STDS"},{"issue":"Suppl 1","key":"1687_CR7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2893.2011.01526.x","volume":"19","author":"B Kronenberger","year":"2012","unstructured":"Kronenberger B, Zeuzem S (2012) New developments in HCV therapy. J Viral Hepat 19(Suppl 1):48\u201351","journal-title":"J Viral Hepat"},{"key":"1687_CR8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","volume":"6","author":"MP Manns","year":"2007","unstructured":"Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F et al (2007) The way forward in HCV treatment\u2013finding the right path. Nat Rev Drug Discov 6:991\u20131000","journal-title":"Nat Rev Drug Discov"},{"key":"1687_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","volume":"70","author":"X Tong","year":"2006","unstructured":"Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J et al (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28\u201338","journal-title":"Antiviral Res"},{"key":"1687_CR10","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","volume":"8","author":"KP Romano","year":"2012","unstructured":"Romano KP, Ali A, Aydin C, Soumana D, Ozen A et al (2012) The molecular basis of drug resistance against Hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog 8:e1002832","journal-title":"PLoS Pathog"},{"key":"1687_CR11","doi-asserted-by":"crossref","first-page":"267483","DOI":"10.1155\/2012\/267483","volume":"2012","author":"CS Strahotin","year":"2012","unstructured":"Strahotin CS, Babich M (2012) Hepatitis C variability, patterns of resistance, and impact on therapy. Adv Virol 2012:267483","journal-title":"Adv Virol"},{"issue":"Suppl 1","key":"1687_CR12","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","volume":"55","author":"LE Taylor","year":"2012","unstructured":"Taylor LE, Swan T, Mayer KH (2012) HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 55(Suppl 1):S33\u2013S42","journal-title":"Clin Infect Dis"},{"key":"1687_CR13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drudis.2007.01.009","volume":"12","author":"Y He","year":"2007","unstructured":"He Y, Duan W, Tan SL (2007) Emerging host cell targets for hepatitis C therapy. Drug Discov Today 12:209\u2013217","journal-title":"Drug Discov Today"},{"key":"1687_CR14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nbt1207-1383","volume":"25","author":"SL Tan","year":"2007","unstructured":"Tan SL, Ganji G, Paeper B, Proll S, Katze MG (2007) Systems biology and the host response to viral infection. Nat Biotechnol 25:1383\u20131389","journal-title":"Nat Biotechnol"},{"key":"1687_CR15","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2165\/00003495-200767130-00015","volume":"67","author":"VR Anderson","year":"2007","unstructured":"Anderson VR, Curran MP (2007) Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67:1947\u20131967","journal-title":"Drugs"},{"key":"1687_CR16","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00078-08","volume":"52","author":"BE Korba","year":"2008","unstructured":"Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS (2008) Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 52:4069\u20134071","journal-title":"Antimicrob Agents Chemother"},{"key":"1687_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.antiviral.2011.05.017","volume":"91","author":"C Yon","year":"2011","unstructured":"Yon C, Viswanathan P, Rossignol JF, Korba B (2011) Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells. Antiviral Res 91:233\u2013240","journal-title":"Antiviral Res"},{"key":"1687_CR18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","volume":"137","author":"M Elazar","year":"2009","unstructured":"Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA et al (2009) The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 137:1827\u20131835","journal-title":"Gastroenterology"},{"key":"1687_CR19","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1128\/MCB.18.9.5208","volume":"18","author":"M Gale Jr","year":"1998","unstructured":"Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M et al (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18:5208\u20135218","journal-title":"Mol Cell Biol"},{"key":"1687_CR20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","volume":"334","author":"N Enomoto","year":"1996","unstructured":"Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T et al (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77\u201381","journal-title":"N Engl J Med"},{"key":"1687_CR21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0928-0197(98)00034-8","volume":"10","author":"MJ Gale Jr","year":"1998","unstructured":"Gale MJ Jr, Korth MJ, Katze MG (1998) Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10:157\u2013162","journal-title":"Clin Diagn Virol"},{"key":"1687_CR22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/gut.2003.031336","volume":"53","author":"M Pascu","year":"2004","unstructured":"Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U et al (2004) Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53:1345\u20131351","journal-title":"Gut"},{"key":"1687_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2893.2010.01287.x","volume":"18","author":"TM Chen","year":"2011","unstructured":"Chen TM, Huang PT, Wen CF, Tung JN, Chow KC et al (2011) Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. J Viral Hepat 18:119\u2013128","journal-title":"J Viral Hepat"},{"key":"1687_CR24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.antiviral.2011.10.006","volume":"92","author":"N Laufer","year":"2011","unstructured":"Laufer N, Abusamra L, Bolcic F, Gun A, Rolon MJ et al (2011) No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30\u00a0days course of nitazoxanide monotherapy. Antiviral Res 92:497\u2013499","journal-title":"Antiviral Res"},{"key":"1687_CR25","doi-asserted-by":"crossref","first-page":"e1002696","DOI":"10.1371\/journal.ppat.1002696","volume":"8","author":"TK Scheel","year":"2012","unstructured":"Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM et al (2012) Analysis of functional differences between Hepatitis C virus NS5A of genotypes 1\u20137 in infectious cell culture systems. PLoS Pathog 8:e1002696","journal-title":"PLoS Pathog"},{"key":"1687_CR26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/nar\/gki198","volume":"33","author":"K Katoh","year":"2005","unstructured":"Katoh K, Kuma K, Toh H, Miyata T (2005) MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 33:511\u2013518","journal-title":"Nucleic Acids Res"},{"key":"1687_CR27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2008.06.030","volume":"49","author":"YH Tsai","year":"2008","unstructured":"Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY et al (2008) The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 49:899\u2013907","journal-title":"J Hepatol"},{"key":"1687_CR28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2036.2008.03781.x","volume":"28","author":"JF Rossignol","year":"2008","unstructured":"Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB (2008) Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28:574\u2013580","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"1687_CR29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1478-3231.2011.02704.x","volume":"32","author":"G Esmat","year":"2012","unstructured":"Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME (2012) The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 32(Suppl 1):146\u2013150","journal-title":"Liver Int"},{"key":"1687_CR30","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1128\/JCM.02109-12","volume":"50","author":"A El-Shamy","year":"2012","unstructured":"El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L et al (2012) NS5A sequence heterogeneity of Hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 50:3886\u20133892","journal-title":"J Clin Microbiol"},{"key":"1687_CR31","unstructured":"Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucleic Acids Symposium Series, pp 91\u201398"},{"key":"1687_CR32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/bioinformatics\/14.9.817","volume":"14","author":"D Posada","year":"1998","unstructured":"Posada D, Crandall KA (1998) MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817\u2013818","journal-title":"Bioinformatics"},{"key":"1687_CR33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10635150390235520","volume":"52","author":"S Guindon","year":"2003","unstructured":"Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52:696\u2013704","journal-title":"Syst Biol"},{"key":"1687_CR34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/1471-2105-8-460","volume":"8","author":"DH Huson","year":"2007","unstructured":"Huson DH, Richter DC, Rausch C, Dezulian T, Franz M et al (2007) Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinforma 8:460","journal-title":"BMC Bioinforma"},{"key":"1687_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2012.05.015","volume":"95","author":"F Bolcic","year":"2012","unstructured":"Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R et al (2012) Longitudinal analysis of the 5\u2032UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Res 95:72\u201381","journal-title":"Antiviral Res"},{"key":"1687_CR36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00705-012-1230-1","volume":"157","author":"F Bolcic","year":"2012","unstructured":"Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M et al (2012) Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch Virol 157:703\u2013711","journal-title":"Arch Virol"},{"key":"1687_CR37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2893.2009.01169.x","volume":"17","author":"HJ Yuan","year":"2010","unstructured":"Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM (2010) Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat 17:208\u2013216","journal-title":"J Viral Hepat"},{"key":"1687_CR38","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1086\/379037","volume":"188","author":"A Boulestin","year":"2003","unstructured":"Boulestin A, Sandres-Saune K, Payen JL, Rostaing L, Pasquier C et al (2003) Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha. J Infect Dis 188:1367\u20131370","journal-title":"J Infect Dis"},{"key":"1687_CR39","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1086\/521306","volume":"196","author":"F Dal Pero","year":"2007","unstructured":"Dal Pero F, Tang KH, Gerotto M, Bortoletto G, Paulon E et al (2007) Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. J Infect Dis 196:998\u20131005","journal-title":"J Infect Dis"},{"key":"1687_CR40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","volume":"436","author":"M Gale Jr","year":"2005","unstructured":"Gale M Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436:939\u2013945","journal-title":"Nature"},{"key":"1687_CR41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1365-2893.2006.00739.x","volume":"13","author":"T Kohashi","year":"2006","unstructured":"Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H et al (2006) Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 13:582\u2013590","journal-title":"J Viral Hepat"},{"key":"1687_CR42","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","volume":"85","author":"A Macdonald","year":"2004","unstructured":"Macdonald A, Harris M (2004) Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485\u20132502","journal-title":"J Gen Virol"},{"key":"1687_CR43","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1053\/jhep.2001.24749","volume":"33","author":"P Podevin","year":"2001","unstructured":"Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A et al (2001) Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 33:1503\u20131511","journal-title":"Hepatology"},{"key":"1687_CR44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1023\/A:1015349924116","volume":"47","author":"MD Murphy","year":"2002","unstructured":"Murphy MD, Rosen HR, Marousek GI, Chou S (2002) Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 47:1195\u20131205","journal-title":"Dig Dis Sci"},{"key":"1687_CR45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/jmv.22144","volume":"83","author":"N Yahoo","year":"2011","unstructured":"Yahoo N, Sabahi F, Shahzamani K, Malboobi MA, Jabbari H et al (2011) Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment. J Med Virol 83:1332\u20131337","journal-title":"J Med Virol"},{"key":"1687_CR46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2012.05.015","volume":"95","author":"F Bolcic","year":"2012","unstructured":"Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R et al (2012) Longitudinal analysis of the 5\u2032UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Res 95:72\u201381","journal-title":"Antiviral Res"},{"key":"1687_CR47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1665-2681(19)31800-9","volume":"8","author":"I Mederacke","year":"2009","unstructured":"Mederacke I, Wedemeyer H (2009) Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? Ann Hepatol 8:166\u2013168","journal-title":"Ann Hepatol"},{"key":"1687_CR48","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1128\/JCM.02109-12","volume":"50","author":"A El-Shamy","year":"2012","unstructured":"El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L et al (2012) NS5A sequence heterogeneity of Hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon\/ribavirin therapy in Egyptian patients. J Clin Microbiol 50:3886\u20133892","journal-title":"J Clin Microbiol"},{"key":"1687_CR49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1478-3231.2010.02283.x","volume":"30","author":"T Asselah","year":"2010","unstructured":"Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S et al (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30:1259\u20131269","journal-title":"Liver Int"},{"key":"1687_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00535-012-0669-x","volume":"48","author":"WL Chuang","year":"2012","unstructured":"Chuang WL, Yu ML (2012) Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 48:22\u201330","journal-title":"J Gastroenterol"},{"key":"1687_CR51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3851\/IMP2026","volume":"17","author":"CH Liu","year":"2012","unstructured":"Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL et al (2012) Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 17:477\u2013484","journal-title":"Antivir Ther"},{"key":"1687_CR52","doi-asserted-by":"crossref","first-page":"e30513","DOI":"10.1371\/journal.pone.0030513","volume":"7","author":"A El-Shamy","year":"2012","unstructured":"El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S et al (2012) Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon\/ribavirin therapy. PLoS One 7:e30513","journal-title":"PLoS One"},{"key":"1687_CR53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hep.22339","volume":"48","author":"A El-Shamy","year":"2008","unstructured":"El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR et al (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy. Hepatology 48:38\u201347","journal-title":"Hepatology"},{"key":"1687_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000322219","volume":"55","author":"A El-Shamy","year":"2012","unstructured":"El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S et al (2012) Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon\/ribavirin combination therapy. Intervirology 55:1\u201311","journal-title":"Intervirology"},{"key":"1687_CR55","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3892\/ijmm.2012.1093","volume":"30","author":"Y Yano","year":"2012","unstructured":"Yano Y, Seo Y, Miki A, Saito M, Kato H et al (2012) Mutations in non-structural 5A and rapid viral response to pegylated interferon-alpha-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Int J Mol Med 30:1048\u20131052","journal-title":"Int J Mol Med"},{"key":"1687_CR56","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1128\/JVI.75.13.6095-6106.2001","volume":"75","author":"SJ Polyak","year":"2001","unstructured":"Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G et al (2001) Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75:6095\u20136106","journal-title":"J Virol"},{"key":"1687_CR57","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1128\/JVI.00533-12","volume":"86","author":"K Kumthip","year":"2012","unstructured":"Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN et al (2012) Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 86:8581\u20138591","journal-title":"J Virol"},{"key":"1687_CR58","doi-asserted-by":"crossref","first-page":"12614","DOI":"10.1128\/JVI.05240-11","volume":"85","author":"VR Sanghvi","year":"2011","unstructured":"Sanghvi VR, Steel LF (2011) The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol 85:12614\u201312621","journal-title":"J Virol"},{"key":"1687_CR59","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1074\/jbc.272.13.8388","volume":"272","author":"SR Brand","year":"1997","unstructured":"Brand SR, Kobayashi R, Mathews MB (1997) The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J Biol Chem 272:8388\u20138395","journal-title":"J Biol Chem"},{"key":"1687_CR60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rmv.674","volume":"21","author":"G Clerzius","year":"2011","unstructured":"Clerzius G, Gelinas JF, Gatignol A (2011) Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol 21:42\u201353","journal-title":"Rev Med Virol"},{"key":"1687_CR61","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s12272-011-0921-6","volume":"34","author":"C Lee","year":"2011","unstructured":"Lee C (2011) Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Arch Pharm Res 34:1403\u20131407","journal-title":"Arch Pharm Res"},{"key":"1687_CR62","unstructured":"Osinusi AWC, Zhang X, Shivabesan G, Shivakumar B, Silk R, Doonquah L, Henn S, Teferi G, Masur H, Kottilil S, Fishbein D (2012) Augmentation of Interferon signaling pathway by Nitazoxanide: a therapeutic strategy for HIV\/HCV Coinfected Relapsers to Peg-interferon and Ribavirin therapy. In: 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, USA"},{"key":"1687_CR63","unstructured":"Amorosa VU, T, Johnson V, Kang M, Luetkemeyer A, Bardin M, Haas D, Chung R, Yesmin S, Coughlin K, Martinez A, Adams MB, Alston-Smith B, Tebas P, Peters M (2012) The addition of nitazoxanide to peginterferon alfa-2a and ribavirin does not significantly improve sustained virologic response in HCV treatment-na\u00efve genotype 1 HIV-1\/HCV co-infected subjects: results of ACTG 5269. XIX International AIDS Conference. Washington, USA"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-013-1687-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-013-1687-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-013-1687-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T07:42:31Z","timestamp":1715154151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-013-1687-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s00705-013-1687-6","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}